Experimental Approaches for the Treatment of Malignant Gliomas

Overview

Journal Pharmacol Ther

Specialty Pharmacology

Date 2010 Jun 16

PMID 20546782

Citations 33

Authors

Leopold Arko

Igor Katsyv

Grace E Park

William Patrick Luan

John K Park

Affiliations

Soon will be listed here.

Abstract

Malignant gliomas, which include glioblastomas and anaplastic astrocytomas, are the most common primary tumors of the brain. Over the past 30 years, the standard treatment for these tumors has evolved to include maximal safe surgical resection, radiation therapy and temozolomide chemotherapy. While the median survival of patients with glioblastomas has improved from 6 months to 14.6 months, these tumors continue to be lethal for the vast majority of patients. There has, however, been recent substantial progress in our mechanistic understanding of tumor development and growth. The translation of these genetic, epigenetic and biochemical findings into therapies that have been tested in clinical trials is the subject of this review.

Citing Articles

Exploratory Study on Nanoparticle Co-Delivery of Temozolomide and Ligustilide for Enhanced Brain Tumor Therapy.

Ke G, Zhang M, Hu P, Zhang J, Naeem A, Wang L Pharmaceutics. 2025; 17(2).

PMID: 40006558 PMC: 11858958. DOI: 10.3390/pharmaceutics17020191.

Ultrasmall solid lipid nanoparticles as a potential innovative delivery system for a drug combination against glioma.

Battaglia L, Dianzani C, Muntoni E, Marini E, Bozza A, Bordano V Nanomedicine (Lond). 2024; 20(1):37-52.

PMID: 39611709 PMC: 11703491. DOI: 10.1080/17435889.2024.2434452.

Cell Membrane Fragment-Wrapped Parenteral Nanoemulsions: A New Drug Delivery Tool to Target Gliomas.

Dianzani C, Bozza A, Bordano V, Cangemi L, Ferraris C, Foglietta F Cells. 2024; 13(7.

PMID: 38607080 PMC: 11011487. DOI: 10.3390/cells13070641.

Tumor Niches: Perspectives for Targeted Therapies in Glioblastoma.

Srivastava R, Dodda M, Zou H, Li X, Hu B Antioxid Redox Signal. 2023; 39(13-15):904-922.

PMID: 37166370 PMC: 10654996. DOI: 10.1089/ars.2022.0187.

si-PDGFR-Loaded Exosomes Suppress the Progression of Glioma by Inhibiting the Oxidative Associated PI3K/Akt/EZH2 Signaling Pathway.

Li Y, Yu H, Ma Q, Wei M, Liu X, Qi Y Oxid Med Cell Longev. 2022; 2022:5081439.

PMID: 36275907 PMC: 9586723. DOI: 10.1155/2022/5081439.

References

Rampling R, Cruickshank G, Papanastassiou V, Nicoll J, Hadley D, Brennan D . Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther. 2000; 7(10):859-66. DOI: 10.1038/sj.gt.3301184. View

Vredenburgh J, Desjardins A, Herndon 2nd J, Dowell J, Reardon D, Quinn J . Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007; 13(4):1253-9. DOI: 10.1158/1078-0432.CCR-06-2309. View

Fountzilas G, Karkavelas G, Kalogera-Fountzila A, Karina M, Ignatiadis M, Koukoulis G . Post-operative combined radiation and chemotherapy with temozolomide and irinotecan in patients with high-grade astrocytic tumors. A phase II study with biomarker evaluation. Anticancer Res. 2007; 26(6C):4675-86. View

Sharif T, Sharif M . Overexpression of protein kinase C epsilon in astroglial brain tumor derived cell lines and primary tumor samples. Int J Oncol. 1999; 15(2):237-43. View

Hsu S, Volpert O, Steck P, Mikkelsen T, Polverini P, Rao S . Inhibition of angiogenesis in human glioblastomas by chromosome 10 induction of thrombospondin-1. Cancer Res. 1996; 56(24):5684-91. View

Brandes A, Tosoni A, Basso U, Reni M, Valduga F, Silvio Monfardini . Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). J Clin Oncol. 2004; 22(23):4779-86. DOI: 10.1200/JCO.2004.06.181. View

Burgess T, Coxon A, Meyer S, Sun J, Rex K, Tsuruda T . Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. Cancer Res. 2006; 66(3):1721-9. DOI: 10.1158/0008-5472.CAN-05-3329. View

Weaver M, Laske D . Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J Neurooncol. 2003; 65(1):3-13. DOI: 10.1023/a:1026246500788. View

Schmidt-Wolf G, Negrin R, Schmidt-Wolf I . Activated T cells and cytokine-induced CD3+CD56+ killer cells. Ann Hematol. 1997; 74(2):51-6. DOI: 10.1007/s002770050257. View

10.

Mineta T, Rabkin S, Martuza R . Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res. 1994; 54(15):3963-6. View

11.

Wong A, Bigner S, Bigner D, Kinzler K, Hamilton S, Vogelstein B . Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci U S A. 1987; 84(19):6899-903. PMC: 299192. DOI: 10.1073/pnas.84.19.6899. View

12.

Hau P, Jachimczak P, Schlingensiepen R, Schulmeyer F, Jauch T, Steinbrecher A . Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies. Oligonucleotides. 2007; 17(2):201-12. DOI: 10.1089/oli.2006.0053. View

13.

Lustig R, Mikkelsen T, Lesser G, Grossman S, Ye X, Desideri S . Phase II preradiation R115777 (tipifarnib) in newly diagnosed GBM with residual enhancing disease. Neuro Oncol. 2008; 10(6):1004-9. PMC: 2718997. DOI: 10.1215/15228517-2008-070. View

14.

Kinzler K, Bigner S, Bigner D, Trent J, Law M, OBrien S . Identification of an amplified, highly expressed gene in a human glioma. Science. 1987; 236(4797):70-3. DOI: 10.1126/science.3563490. View

15.

Reardon D, Quinn J, Vredenburgh J, Gururangan S, Friedman A, Desjardins A . Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. Clin Cancer Res. 2006; 12(3 Pt 1):860-8. DOI: 10.1158/1078-0432.CCR-05-2215. View

16.

Newton H . Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 1: Growth factor and Ras signaling pathways. Expert Rev Anticancer Ther. 2003; 3(5):595-614. DOI: 10.1586/14737140.3.5.595. View

17.

Jaeckle K, Eyre H, Townsend J, Schulman S, Knudson H, Belanich M . Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study. J Clin Oncol. 1998; 16(10):3310-5. DOI: 10.1200/JCO.1998.16.10.3310. View

18.

Ruoslahti E . Integrins. J Clin Invest. 1991; 87(1):1-5. PMC: 294975. DOI: 10.1172/JCI114957. View

19.

Hayes R, Koslow M, Hiesiger E, Hymes K, Hochster H, Moore E . Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma. Cancer. 1995; 76(5):840-52. DOI: 10.1002/1097-0142(19950901)76:5<840::aid-cncr2820760519>3.0.co;2-r. View

20.

Todo T, Martuza R, Rabkin S, Johnson P . Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci U S A. 2001; 98(11):6396-401. PMC: 33479. DOI: 10.1073/pnas.101136398. View